Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Tyra Biosciences, Inc. (TYRA) stock, including its current price, historical data, performance metrics, and key financial information. It details the company's biotechnology focus on precision medicines for FGFR biology and highlights its lead product candidates and clinical trials. The article also includes analyst insights and performance comparisons against the S&P 500.
Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History
Tyra Biosciences, Inc. (TYRA) stock closed at $20.43, down 2.76%, on October 2, 2026. The clinical-stage biotechnology company focuses on developing precision medicines for fibroblast growth factor receptor (FGFR) biology, with lead product candidates for various cancers and genetic conditions. Analysts have an average target price of $47.45 for TYRA, with a "Strong Buy" recommendation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (NASDAQ: TYRA) following a significant stock price drop. The investigation concerns potential securities fraud or unlawful business practices, particularly after the company announced initial Phase 2 study results for dabogratinib, which led to a 17.66% decline in stock value due to concerns about adverse events. Investors who suffered losses are encouraged to contact the law firm.
Will Phase 2 Safety Concerns Change Tyra Biosciences Stock Narrative
Tyra Biosciences is facing legal scrutiny from Bronstein, Gewirtz & Grossman, LLC due
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences, Inc. (NASDAQ: TYRA) on behalf of investors. This investigation follows a 17.66% drop in Tyra's stock price on September 9, 2026, after the company announced initial results from its SURF302 Phase 2 study, which included reports of Grade 3 treatment-emergent adverse events in some participants. Investors are encouraged to contact the law firm for more information regarding the class action investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tyra Biosciences, Inc. (TYRA) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential claims against Tyra Biosciences, Inc. (TYRA) following a significant drop in its stock price. This drop occurred after Tyra released initial results from its SURF302 study, which, despite indicating a favorable safety profile, also reported Grade 3 treatment-emergent adverse events in some participants. The firm is encouraging investors who purchased Tyra securities to join the investigation.
Tyra Biosciences, Inc. (TYRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Tyra Biosciences, Inc. (TYRA) following a significant stock price drop. The investigation stems from the release of initial Phase 2 study results for dabogratinib, which, despite a favorable safety profile, noted Grade 3 treatment-emergent adverse events in some participants, leading to a 17.66% decrease in Tyra's stock. Shareholders who purchased Tyra securities are encouraged to contact the firm to learn more and potentially assist with the investigation.
Bank of America Corp DE Purchases 349,732 Shares of Tyra Biosciences, Inc. $TYRA
Bank of America Corp DE has acquired 349,732 shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the second quarter, valued at approximately $11.17 million, representing a 0.59% stake in the company. Institutional investors now collectively own 84.14% of Tyra Biosciences. Despite a recent stock decline, missing earnings estimates, and a "sell" rating from Weiss Ratings, analysts maintain a "Moderate Buy" consensus with an average target price of $46.89, expecting narrower losses in the future.
Oppenheimer Adjusts Price Target on Tyra Bioscience to $40 From $50, Keeps Outperform Rating
Oppenheimer has lowered its price target for Tyra Bioscience (TYRA) to $40 from $50, while maintaining an Outperform rating on the stock. Despite the adjustment, the biotech company still holds an average "buy" rating with a mean price target of $47.45 among analysts. This article is marked as premium content, requiring a subscription to view the full details.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89
Tyra Biosciences (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from fourteen research firms, with an average one-year price target of $46.89, significantly above its recent trading price of $22.41. While analysts like HC Wainwright have raised future EPS estimates due to expectations of narrower losses, others like Oppenheimer have lowered price targets, indicating mixed views. The clinical-stage biotechnology company remains unprofitable and its valuation is highly dependent on clinical progress, execution, and funding.
ETFs Investing in Tyra Bioscience, Inc Stocks
This article lists various Exchange Traded Funds (ETFs) that hold shares of Tyra Bioscience, Inc. (TYRA). The ETFs are sorted by market value and include details such as their weight in TYRA, issuer, management style, expense ratio, assets under management (AUM), and performance metrics. This information helps investors identify diversified investment opportunities involving Tyra Bioscience with potentially lower risk.
Equities Analysts Set Expectations for TYRA FY2026 Earnings
HC Wainwright has revised its FY2026 EPS forecast for Tyra Biosciences (NASDAQ:TYRA) to a loss of $2.60 per share, an improvement from its previous estimate, while maintaining a "Buy" rating and a $29 price target. Despite missing the consensus EPS estimate for its last quarter, analysts largely remain positive on the stock, which holds a "Moderate Buy" consensus rating and an average price target of $46.89. Institutional investors, including Jupiter Topco and BlackRock, have significantly increased their stakes in the company, which opened down 9.2% at $23.23.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tyra Biosciences, Inc. (TYRA) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Tyra Biosciences, Inc. (TYRA) following a significant drop in its stock price. This decline occurred after the company released initial Phase 2 study results for dabogratinib, which, despite indicating a favorable safety profile, reported Grade 3 treatment-emergent adverse events in a notable percentage of participants. The firm is encouraging investors who purchased Tyra securities to join their investigation into the matter.
Tyra Biosciences (NASDAQ:TYRA) Trading Down 6.7% on Analyst Downgrade
Tyra Biosciences (NASDAQ:TYRA) saw its stock fall by 6.7% after HC Wainwright downgraded its price target from $30 to $29, while maintaining a "Buy" rating. Despite the downgrade, the overall analyst consensus remains "Moderate Buy" with an average price target of $46.89. The company recently missed quarterly EPS expectations and analysts project a full-year loss of $2.73 per share.
Oppenheimer reiterates Outperform rating on Tyra Biosciences, $40 price target
Oppenheimer has reiterated an Outperform rating for Tyra Biosciences (TYRA) with a $40 price target, representing a 55.9% upside from its Sep 21 close. The firm highlights Tyra's strong pipeline of FGFR-targeted therapies designed to overcome limitations of existing inhibitors and its innovative SNAP platform for rapid, data-driven drug design. These factors position Tyra Biosciences as a compelling investment in the biotechnology sector.
Oppenheimer Adjusts Price Target on Tyra Bioscience to $40 From $50, Keeps Outperform Rating
Oppenheimer has lowered its price target for Tyra Bioscience (TYRA) to $40 from $50, while maintaining an "Outperform" rating on the stock. The adjustment was reported by MT Newswires on September 22, 2026, at 09:13 am EDT. The full article content is reserved for members of the platform.
H.C. Wainwright cuts Tyra Biosciences price target to $29 on dilution
H.C. Wainwright has lowered its price target for Tyra Biosciences (NASDAQ: TYRA) to $29 from $30, while maintaining a Buy rating. This reduction is attributed to dilution from a recent capital raise, despite the company's strong balance sheet. The firm also noted preliminary Phase 2 data from Abbisko Therapeutics' lavengratinib for achondroplasia, but awaits Tyra's own BEACH301 trial data expected in Q1 2027.
Biotech fund group reports stake in Tyra Biosciences (NASDAQ: TYRA) — here’s how much of the company it holds
A group of investment entities led by Biotechnology Value Fund (BVF) and Mark N. Lampert has reported a collective beneficial ownership of 4,215,886 shares of Tyra Biosciences (TYRA) common stock, representing approximately 6.1% of the outstanding shares as of September 21, 2026. The stake is distributed among several affiliated funds, with BVF holding 3.2%, BVF2 holding 2.4%, and Biotechnology Value Trading Fund OS holding less than 1%. Various entities within the group share voting and dispositive power, though some disclaim beneficial ownership of shares held by affiliates.
TYRA - Oral FGFR3 Therapy And Multi Indication Expansion Will Reshape Long Term Prospects
Tyra Biosciences is poised for long-term growth with its oral FGFR3 therapy, dabogratinib, targeting multiple indications including NMIBC, UTUC, and achondroplasia. Analysts anticipate significant revenue potential, projecting $19.5 million by 2029, despite current unprofitability and ongoing litigation risks. The company's strong cash position supports parallel development of its diverse pipeline.
Press Releases about Tyra Biosciences, Inc. - Common Stock (Nasdaq:TYRA)
This article compiles recent press releases concerning Tyra Biosciences, Inc. (NASDAQ: TYRA). It highlights two separate investigations by law firms, Pomerantz LLP and The Schall Law Firm, into potential claims on behalf of investors of Tyra Biosciences. Both investigations cite possible violations of securities laws.
RA Capital Management Acquires Over 9 Million Derivative Securities in Tyra Biosciences (NASDAQ: TYRA)
RA Capital Management has significantly increased its stake in Tyra Biosciences (NASDAQ: TYRA) by purchasing over 9 million derivative securities. This acquisition, which took place on September 15, 2026, at $22.03 per share, brings RA Capital's total holdings to over 11.6 million derivative securities, representing approximately 78.1% of their post-transaction position. The transaction is classified as an open-market purchase, underscoring a strong insider acquisition in the biotechnology firm.
Fuhrman Alan Acquires Additional 951 Shares, Holding 37,115 Tyra Biosciences Stocks Post-Award
Fuhrman Alan, the Chief Financial Officer of Tyra Biosciences (NASDAQ:TYRA), was granted an additional 951 shares of the company's stock at $9.13 per share. This transaction increases his total holdings to 37,115 shares. The award, identified by the SEC transaction code "A," represents approximately 2.6% of his overall ownership in Tyra Biosciences.
Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History
Tyra Biosciences, Inc. (TYRA) stock closed at $24.43 on September 17, 2026, with a slight gain in after-hours trading. The clinical-stage biotechnology company focuses on developing precision medicines for fibroblast growth factor receptor (FGFR) biology, with lead product candidates in trials for various cancers and genetic syndromes. Analysts have an average target price of $48.30 for TYRA, with Wedbush reiterating an Outperform rating.
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets
The provided content does not contain an article but rather a privacy consent form from Yahoo. Therefore, it is impossible to summarize any article content or discuss Tyra Biosciences (TYRA) stock pricing. The content is exclusively about cookie preferences and privacy choices.
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?
Tyra Biosciences (TYRA) reported initial Phase 2 SURF302 results for dabogratinib, an investigational oral FGFR3 inhibitor for bladder cancer, showing a 57% complete response rate and a 79% objective response rate in the primary efficacy analysis. The company plans to advance to Phase 3 discussions with health authorities, supported by manageable safety profiles. While initial results are promising, larger samples and longer follow-up are needed to confirm durable disease control and recurrence prevention.
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tyra Biosciences announced the pricing of a $400 million underwritten offering of common stock and pre-funded warrants. The company plans to use the net proceeds, along with existing funds, to advance its "dabogratinib 3x3" development strategy for LG-UTUC, IR NMIBC, and achondroplasia, as well as support preclinical and drug discovery programs. The offering is expected to close on September 15, 2026, and was led by RA Capital Management with participation from various institutional investors.
Update: Tyra Bioscience Shares Rise After Pricing $400 Million Offering
Tyra Bioscience's shares increased following the pricing of a $400 million offering. The article from MT Newswires, dated September 14, 2026, details this stock price movement. Access to the full article requires a premium subscription.
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $30
H.C. Wainwright has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) but has adjusted its target price down to $30. This decision reflects the firm's continued confidence in the company's prospects despite a revised valuation.
Dabogratinib Shows Early Activity in FGFR3-Altered Low-Grade NMIBC
Initial phase 2 SURF302 data show dabogratinib, an oral FGFR3-selective inhibitor, achieved a 79% overall response rate in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. The treatment demonstrated a favorable safety profile, with most adverse events being mild to moderate. These results support further evaluation of dabogratinib as a potential adjuvant therapy, with plans for a phase 3 study.
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Tyra Biosciences' stock dropped 22% after its experimental bladder cancer pill, dabogratinib, failed to impress in its latest data release. The company is developing this oral treatment for early-stage bladder cancer, competing with Johnson & Johnson in the field. The underwhelming data has led to a lack of confidence in the drug's potential.
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
Tyra Biosciences shares dropped 30% after releasing initial Phase 2 SURF302 trial results for dabogratinib, a drug for FGFR3-altered non-muscle invasive bladder cancer. While the drug showed a 79% overall response rate and 64% complete response rate at a 60 mg dose, the market reacted negatively. The company plans further dosing cohorts and discussions for a potential Phase 3 study.
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
Tyra Biosciences has announced initial positive results from its Phase 2 SURF302 study for dabogratinib, an oral treatment for FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study demonstrated favorable safety and tolerability, with a high overall response rate (ORR) and complete response (CR) rate, particularly in patients with single marker lesions, supporting its potential as a first-line oral adjuvant therapy. These findings pave the way for a planned registrational Phase 3 study and suggest exploring higher doses for patients with multiple marker lesions.
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
Tyra Biosciences, a clinical-stage biotechnology company, announced its participation in the Cantor Global Healthcare Conference. The company will present via a virtual fireside chat and hold one-on-one investor meetings on Wednesday, September 9, 2026, at 1:00 PM ET. A live webcast of the presentation will be available on the company's website.
Piper Sandler reiterates Tyra Biosciences stock rating ahead of data By Investing.com
Piper Sandler has reiterated an Overweight rating and a $56.00 price target for Tyra Biosciences (NASDAQ:TYRA) in anticipation of clinical trial data for dabogratinib. The firm expects a 70% three-month complete response rate with good safety as the success threshold for the drug in intermediate-risk non-muscle invasive bladder cancer, which could lead to a Phase 3 trial. Tyra Biosciences is also a 2026 top pick for Piper Sandler, with the drug dabogratinib seen as a potential $1 billion opportunity.
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Tyra Biosciences, Inc. (Nasdaq: TYRA) announced it will host a conference call and webcast on September 9, 2026, at 8:00 am ET to discuss initial clinical results from its SURF302 Phase 2 study. This study evaluates oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The company specializes in developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology and has several other clinical-stage programs.
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Tyra Biosciences will host a conference call and webcast on September 9, 2026, at 8:00 am ET to discuss initial clinical results from its SURF302 Phase 2 study of oral dabogratinib. This drug is being evaluated for intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The company, a clinical-stage biotechnology firm, focuses on developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50
CCORF has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) and maintained its target price at $50. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
Tyra’s one-drug, three-indication bet nears its first phase 2 test
Tyra Biosciences is on the verge of its first Phase 2 clinical test for dabogratinib, an oral FGFR3 inhibitor. This single drug is being developed for two types of urothelial cancer and achondroplasia, a rare bone-growth condition, all linked by mutations in the FGFR3 gene. The company aims to provide a transformative treatment for these unmet medical needs by precisely modulating FGFR3 activity.
Tyra Biosciences Number of Employees 2026 | Employee Count & Headcount Data
Tyra Biosciences (NASDAQ: TYRA) has grown its global workforce to 99 employees as of March 2026, marking a 102.6% increase since 2023. The company is actively hiring, with 8 active job postings in 2026, and its workforce is primarily concentrated in North America. Employee sentiment is noted as negative but improving, while the average salary is $222,237.
Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA
Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate Buy" consensus rating with an average price target of $46.90. The company reported a quarterly loss of $0.69 per share, missing estimates.
TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake
Nextech VI Oncology SCSp, along with related entities and individuals, has filed an amended Schedule 13G reporting a 6.0% beneficial ownership stake in TYRA Biosciences (TYRA). This amounts to 3,553,585 shares of common stock as of June 30, 2026. The filing indicates that Nextech VI GP S.a. r.l. and its managers Ian Charoub, Costas Constantinides, and Rocco Sgobbo collectively have the power to direct the voting and disposition of these shares, although they disclaim forming a "group" for reporting purposes.
Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake
Farallon Capital Management, L.L.C., along with several related investment entities and individuals, has filed an Amendment No. 2 to a Schedule 13G/A, reporting beneficial ownership of 6,000 shares of Tyra Biosciences (TYRA) common stock, which constitutes a 0% stake as of June 30, 2026. This filing indicates that the reporting group's ownership is now below the 5% threshold requiring more extensive disclosure. The shares are held across various Farallon Funds, with the investment manager and several managing members listed as reporting persons.
Avoiding Lag: Real-Time Signals in (TYRA) Movement
The article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near-term and mid-term sentiment despite a long-term positive outlook. It provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50
CCORF has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US), along with maintaining its target price of $50. This suggests a continued positive outlook from the firm regarding the company's stock performance.
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39
BofA Securities has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) but has revised its price target downward to $39. This adjustment reflects an updated outlook from the firm regarding the company's valuation.
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside
Analysts have slightly cut the average 12-month price target for Tyra Biosciences, Inc. (TYRA) stock from $51.09 to $50.82, with individual forecasts ranging from $39 to $59. This updated target suggests a potential upside of approximately 94% based on the recent closing price. The consensus rating from 15 analysts remains a "Buy."
Tyra Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
Tyra Biosciences Inc (TYRA) reported a quarterly adjusted loss of 50 cents per share for the quarter ended September 30, meeting the average analyst expectation. The company's reported revenue was zero, also matching analyst predictions. Shares of Tyra Biosciences Inc have risen by 7.2% this quarter and 7.9% year-to-date, with analysts maintaining a "strong buy" rating and a median 12-month price target of $32.00.
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53
Wedbush has reiterated its Buy rating for TYRA Biosciences, Inc. (TYRA.US), maintaining a target price of $53. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Jefferies Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42
Jefferies has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and increased its price target to $42. This indicates a positive outlook from the firm regarding the company's future performance.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Tyra Biosciences, Inc. (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from fifteen research firms, with an average 12-month price target of $46.90. Despite this optimistic outlook, the company's shares recently declined by 21% to $25.71, trading below its 50-day and 200-day moving averages. Tyra Biosciences also reported a quarterly loss of $0.69 per share, missing analyst estimates.
